Aralez Pharma (ARLZ) Releases Earnings Results, Beats Expectations By $0.01 EPS

Aralez Pharma (ARLZ) reported quarterly earnings results on Tuesday, Aug-9-2016. The company said it had a profit of $-0.27 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.28. The company posted revenue of $12.60 million in the period, compared to analysts expectations of $11.65 million. The company’s revenue was up 142.3% compared to the same quarter last year.

In a different news, on May 23, 2016, James Patrick Tursi (Chief Medical Officer) purchased 10,000 shares at $3.75 per share price. According to the SEC, on May 18, 2016, Mark A Glickman (Chief Commercial Officer) purchased 25,000 shares at $3.68 per share price. On May 18, 2016, Eric Trachtenberg (GC, CCO & Secretary) purchased 10,000 shares at $3.76 per share price, according to the Form-4 filing with the securities and exchange commission.

Aralez Pharma

Leave a Reply

Aralez Pharma - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aralez Pharma. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.